✦ LIBER ✦

B358 SF1126, A Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequen

✍ Scribed by David, E; Lonial, S; Barwick, B; Peng, X; Kaufman, J; Garlich, J

Book ID: 118629488
Publisher: CIG Media Group, LP.
Year: 2009
Tongue: English
Weight: 96 KB
Volume: 9
Category: Article
ISSN: 1557-9190
DOI: 10.1016/s1557-9190(11)70716-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I pharmacokinetic and pharmacodyna

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

✍ D. Mahadevan; E.G. Chiorean; W.B. Harris; D.D. Von Hoff; A. Stejskal-Barnett; W. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 791 KB

Involvement of the PI3K/Akt pathway in e

Involvement of the PI3K/Akt pathway in estrogen-mediated regulation of human CYP7B1: Identification of CYP7B1 as a novel target for PI3K/Akt and MAPK signalling

✍ Wanjin Tang; Hanna Pettersson; Maria Norlin 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 939 KB

20 VEL015: a novel inhibitor of PI3k/Akt

20 VEL015: a novel inhibitor of PI3k/Akt signalling inhibits the progression of prostate cancer and sensitises to existing therapies

✍ N.M. CORCORAN; D. MARTIN; A.J. COSTELLO; C.M. HOVENS 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 37 KB

132 Intermittent dosing of the MEK inhib

132 Intermittent dosing of the MEK inhibitor, GDC-0973, and the PI3K inhibitor, GDC-0941, results in prolonged accumulation of Bim and causes strong tumor growth inhibition in vivo

✍ M. Belvin; L. Berry; J. Chan; D. den Otter; L. Friedman; K. Hoeflich; H. Koeppen 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB

The efficacy of a novel, dual PI3K/mTOR

The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer

✍ Niranjan Awasthi; Peter L. Yen; Margaret A. Schwarz; Roderich E. Schwarz 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB

## Abstract Gemcitabine has limited clinical benefits for pancreatic ductal adenocarcinoma (PDAC). The phosphatidylinositol‐3‐kinase (PI3K)/AKT and mammalian target of rapamycin (mTOR) signaling pathways are frequently dysregulated in PDAC. We investigated the effects of NVP‐BEZ235, a novel dual PI

358 A Multi-arm Phase 1 Dose Escalation

358 A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer

✍ Britten, C.; Wainberg, Z.; Tabernero, J.; Alsina Maqueda, M.; Leong, S.; Sessa, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 55 KB